KRAS and cancer: When each gene was analyzed alone in multivariate analysis of early stage cancers, FGFR2 mutation status remained a significant factor associated with reduced DFS (HR = 3.24; 95% CI 1.35–7.77; p = 0.008) (Table 3) and KRAS was significantly associated with longer DFS (HR = 0.23 CI 0.05–0.97 p = 0.045).